(Vanderbilt University Medical Center) A drug that targets the immune system can delay the onset of type 1 diabetes an average of two years in children and adults at high risk, according to findings from TrialNet's Teplizumab (anti-CD3) Prevention Study published in the New England Journal of Medicine.
Original Article: Study drug delays type 1 diabetes in high risk children and adults